PIPA564103
CLN3 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA564103-Each-of-1 | In Stock | ₹ 48,905.50 |
PIPA564103 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 48,905.50
GST (18%): ₹ 8,802.99
Total Price: ₹ 57,708.49
Antigen
CLN3
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CLN3
Gene Alias
AI323623; batten disease protein; Battenin; BTS; ceroid lipofuscinosis, neuronal 3, juvenile (Batten, Spielmeyer-Vogt disease); ceroid-lipofuscinosis, neuronal 3; CLN 3; Cln3; CLN3, battenin; Cln3p; JNCL; MGC102840; Protein CLN3
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
1201
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Immunohistochemistry
Concentration
0.1 mg/mL
Formulation
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2
Gene Accession No.
Q13286
Gene Symbols
CLN3
Immunogen
Recombinant protein corresponding to Human CLN3
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Immunogen sequence: EEEAESAARQ PLIRTEAPES KPGSSSSLSL RERWTVF Highest antigen sequence identity to the following orthologs: Mouse - 78%, Rat - 73%
- CLN3 is a highly glycosylated, hydrophobic, 438-amino acid protein with 6 transmembrane domains
- The CLN3 protein localizes to the lysosomal membrane and plays a role in lysosomal function
- It may act as a chaperone involved in the folding and unfolding of other proteins, namely subunit C of the ATP synthase complex
- Mutations in the CLN3 gene cause Batten disease, a recessively inherited neurodegenerative disorder of childhood caused by lysosomal accumulation of hydrophobic material, mainly ATP synthase subunit C
- Batten disease is the most common form of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs)
- Symptoms of Batten disease include progressive loss of vision, seizures, and psychomotor disturbances.